- POAI
positioned as leader in using data, artificial intelligence in search for
novel effective treatments
- Planned
acquisition provides Predictive Oncology with CoRE(TM), a proven
machine-learning framework
- Uniting
CoRE with proprietary PDx tumor-profiling platform and tumor-data database
creates one-of-a-kind, end-to-end “discovery machine”
With its recent proposed acquisition of Carnegie Mellon
spin-out Quantitative Medicine, Predictive Oncology Inc. (NASDAQ: POAI), a leader in using
data and artificial intelligence (AI) to develop personalized cancer therapies,
demonstrates its strong position in assisting in the search for new
anti-cancers, anti-virals, antibiotics and vaccines. POAI’s expertise in this
area is particularly relevant in light of the current race to learn more about
the novel coronavirus 2019-nCoV and identify potential treatments, including
vaccines, to fight the COVID-19 disease.
As organizations around the world rush to find ways to slow
the spread of the COVID-19 outbreak, the importance of AI and machine learning
(ML) in the world of today’s medicine has become increasingly clear (http://ibn.fm/wekHx).
Governments, pharmaceutical companies, universities and others are united in
their focus to develop new diagnostics, vaccines and drug therapies aimed at
the 2019-nCoV virus.
Announcements from Insilico Medicine and MIT point to the increasing
importance of AI and ML in the progress of modern medicine. In addition, both
studies relied on AI and ML approaches that are similar to the CoRE technology
used by QM, which POAI is working to acquire (http://ibn.fm/VVfym). With an agreement in principal in
place, the all-stock acquisition is expected to close this month.
This planned acquisition provides POAI with QM’s proven
machine-learning framework, called CoRE. Developed at CMU and exclusively
licensed to QM, CoRE is a predictive model-building platform for drug screening
and optimization campaigns that uses hybrid machine-learning approaches to
rapidly build predictive models to drive wet-lab experimentation.
Uniting the CoRE approach with the proprietary PDx
tumor-profiling platform and tumor-data database owned by POAI subsidiary
Helomics allows for a one-of-a-kind, end-to-end “discovery machine” (http://ibn.fm/RHsQS). This
approach will “rapidly and cost-effectively generate potential therapeutic
candidates that demonstrate activity against the disease. Therapeutic candidates
developed by this iterative AI and experiment cycle can be fast-tracked, since
there is already demonstrated activity in preclinical laboratory tests rather
than just a computer model.”
Although POAI’s current focus is on cancers, the CoRE
discovery machine could easily be utilized in other critical research,
including the rapid discovery of therapeutics, such as anti-virals. “Given
sufficient resources and access to relevant data, POAI’s CoRE-driven Helomics
discovery machine could soon be at the forefront of the fight against these new
viruses,” POAI’s release noted.
The impact of this collaboration on the healthcare industry
– between POAI’s AI expertise and QM’s CoRe platform – looms large. Insilico
Medicine and MIT illustrate the critical part AI and ML play in the process of
advancing modern medicine. In its announcement, Insilico Medicine shared
molecular structures potentially to targeting the key protein of 2019nCoV. “By
making these structures available to the general public, Insilico hopes those
who are interested in finding a potential treatment for this viral infection
could synthesize and test these molecules,” the announcement said (http://ibn.fm/yYhLv). Insilico
will also “synthesize and test up to 100 molecules using its own resources and
the resources generously offered by its closest partners, to contribute to the
global effort.”
For its part, MIT used an MI algorithm to identify a
powerful new antibiotic compound that “killed many of the world’s most
problematic disease-causing bacteria, including some strains that are resistant
to all known antibiotics,” MIT researchers announced (http://ibn.fm/0sxWn). “It also
cleared infections in two different mouse models. The computer model, which can
screen more than a hundred million chemical compounds in a matter of days, is
designed to pick out potential antibiotics that kill bacteria using different
mechanisms than those of existing drugs.” As healthcare industry leaders
continue to harness the power of AI and ML technologies to improve patient
outcomes, the demand for reliable, data-rich platforms like that of POAI is
only expect to grow.
POAI is bringing precision medicine, or tailored
medical treatment using the individual characteristics of each patient, to the
treatment of cancer. Through its Helomics division, the company leverages its
unique, clinically validated patient derived (PDx) smart tumor profiling
platform to provide oncologists with a roadmap to help individualize therapy.
In addition, the company is leveraging artificial intelligence and its
proprietary database of over 150,000 cancer cases tumors to build
AI-driven predictive models of tumor drug repose to improve outcomes for the patients
of today and tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
